» Articles » PMID: 15131065

Effects of a New Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor on Cl- Conductance in Human Sweat Ducts

Overview
Journal Exp Physiol
Specialty Physiology
Date 2004 May 8
PMID 15131065
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Effective and specific inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel in epithelia has long been needed to better understand the role of anion movements in fluid and electrolyte transport. Until now, available inhibitors have required high concentrations, usually in the millimolar or high micromolar range, to effect even an incomplete block of channel conductance. These inhibitors, including 5-nitro-2(3-phenylpropyl-amino)benzoate (NPPB), bumetamide, glibenclamide and DIDS, are also relatively non-specific. Recently a new anion channel inhibitor, a thiazolidinone derivative, termed CFTRInh-172 has been synthesized and introduced with apparently improved inhibitory properties as shown by effects on anion conductance expressed in cell lines and on secretion in vivo. Here, we assay the effect of this inhibitor on a purely salt absorbing native epithelial tissue, the freshly isolated microperfused human sweat duct, known for its inherently high expression of CFTR. We found that the inhibitor at a maximum dose limited by its aqueous solubility of 5 microm partially blocked CFTR when applied to either surface of the membrane; however, it may be somewhat more effective from the cytosolic side (approximately 70% inhibition). It may also partially inhibit Na+ conductance. The inhibition was relatively slow, with a half time for maximum effect of about 3 min, and showed very slow reversibility. Results also suggest that CFTR Cl- conductance (GCl) was blocked in both apical and basal membranes. The inhibitor appears to exert some effect on Na+ transport as well.

Citing Articles

Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors.

Giuliano K, Wachi S, Drew L, Dukovski D, Green O, Bastos C SLAS Discov. 2017; 23(2):111-121.

PMID: 28898585 PMC: 5784457. DOI: 10.1177/2472555217729790.


Functional reconstitution and channel activity measurements of purified wildtype and mutant CFTR protein.

Eckford P, Li C, Bear C J Vis Exp. 2015; (97).

PMID: 25867140 PMC: 4401239. DOI: 10.3791/52427.


Bioactivity-guided fractionation of an antidiarrheal Chinese herb Rhodiola kirilowii (Regel) Maxim reveals (-)-epicatechin-3-gallate and (-)-epigallocatechin-3-gallate as inhibitors of cystic fibrosis transmembrane conductance regulator.

Chen L, Yu B, Zhang Y, Gao X, Zhu L, Ma T PLoS One. 2015; 10(3):e0119122.

PMID: 25747701 PMC: 4352019. DOI: 10.1371/journal.pone.0119122.


Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Norez C, Vandebrouck C, Bertrand J, Noel S, Durieu E, Oumata N Br J Pharmacol. 2014; 171(21):4831-49.

PMID: 25065395 PMC: 4294108. DOI: 10.1111/bph.12859.


Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from chinese medicinal plants.

Zhang Y, Yu B, Sui Y, Gao X, Yang H, Ma T PLoS One. 2014; 9(4):e94302.

PMID: 24714160 PMC: 3979805. DOI: 10.1371/journal.pone.0094302.